PT - JOURNAL ARTICLE AU - Seidel, Alina AU - Jahrsdörfer, Bernd AU - Körper, Sixten AU - Albers, Dan AU - Maltitz, Pascal von AU - Müller, Rebecca AU - Lotfi, Ramin AU - Wuchter, Patrick AU - Klüter, Harald AU - Schmidt, Michael AU - Münch, Jan AU - Schrezenmeier, Hubert TI - SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays AID - 10.1101/2022.01.17.22269201 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.17.22269201 4099 - http://medrxiv.org/content/early/2022/01/17/2022.01.17.22269201.short 4100 - http://medrxiv.org/content/early/2022/01/17/2022.01.17.22269201.full AB - Background Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about antibody-based COVID-19 therapies. Therefore in this study the in-vitro neutralization capacity against SARS-CoV-2 variants Wuhan D614G, Delta and Omicron in sera of convalescent individuals with and without boost by vaccination was assessed.Methods and Findings This in-vitro study included 66 individuals with a history of SARS-CoV-2 infection, divided into subgroups without (n=29) and with SARS-CoV-2 vaccination (n=37). We measured SARS-CoV-2 antibody concentrations by serological assays (anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S) and neutralizing titers against Wuhan D614G, Delta and Omicron in a pseudovirus neutralization assay.Sera of the majority of unvaccinated convalescents did not effectively neutralize Delta and Omicron (4/29, 13.8% and 19/29, 65.5%, resp.). Neutralizing titers against Wuhan D614G, Delta and Omicron were significantly higher in vaccinated compared to unvaccinated convalescents (p<0.0001) with 11.1, 15.3 and 60-fold higher geometric mean of 50%-neutralizing titers (NT50) in vaccinated compared to unvaccinated convalescents. The increase in neutralizing titers was already achieved by one vaccination dose. Neutralizing titers were highest in the first 3 months after vaccination. Concentrations of anti-S antibodies in the serological assays anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S predict neutralization capacity against Wuhan D614G, Delta and Omicron. While Wuhan D614G was neutralized in-vitro by Bamlanivimab, Casirivimab and Imdevimab, Omicron was resistant to these monoclonal antibodies.Conclusions These findings confirm substantial immune evasion of Delta and Omicron which can be overcome by vaccination of convalescents. This informs strategies for choosing of plasma donors in COVID-19 convalescent plasma programs that shall select specifically vaccinated convalescents with very high titers of anti-S antibodies.Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: B.J., S.K., R.L., R.M., P.W., M.S., H.K. and H.S. are employees of a blood transfusion service collecting plasma including convalescent plasma.Funding StatementThe clinical trials COVIC-19 (EudraCT 021-006621-22) is supported by the Bundesministerium fuer Bildung und Forschung (German Federal Ministry of Education and Research)(www.bmbf.de) and the randomized clinical trial CAPSID (EudraCT including the preparation of convalescent plasma units was supported by the Bundesministerium fuer Gesundheit (German Federal Ministry of Health)(www.bundesgesundheitsministerium.de). H.S., J.M. and H.K. acknowledge funding from the Ministry for Science, Research and the Arts of Baden-Wuerttemberg, Germany (COVID-19 Sonderfoerderlinie, CORE Project)(mwk.baden-wuerttemberg.de). HS acknowledges funding by the European Commission (HORIZON2020 Project SUPPORT-E, no. 101015756). J.M. further acknowledges funding by EU?s Horizon 2020 research and innovation programme (Fight-nCoV, 101003555)(ec.europa.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were approved by the Ethical Committee of University of Ulm and Ethical Committee II, Heidelberg UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.